Crystal structure of Bak bound to the BH3 domain of Bnip5, a noncanonical BH3 domain‐containing protein
Proteins: Structure, Function, and Bioinformatics · 2024
DOI: 10.1002/prot.26568 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proteins: Structure, Function, and Bioinformatics, 2024. Verfasst von Dahwan Lim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Disease Target Structure Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-bcl-2, bcl-2 Homologous Antagonist-Killer Protein. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea Research Institute of Bioscience and Biotechnology, National Research Council of Science and Technology, National Research Foundation of Korea.
Abstract (Originalsprache)
The activation or inactivation of B‐cell lymphoma‐2 (Bcl‐2) antagonist/killer (Bak) is critical for controlling mitochondrial outer membrane permeabilization‐dependent apoptosis. Its pro‐apoptotic activity is controlled by intermolecular interactions with the Bcl‐2 homology 3 (BH3) domain, which is accommodated in the hydrophobic pocket of Bak. Bcl‐2‐interacting protein 5 (Bnip5) is a noncanonical BH3 domain‐containing protein that interacts with Bak. Bnip5 is characterized by its controversial effects on the regulation of the pro‐apoptotic activity of Bak. In the present study, we determined the crystal structure of Bak bound to Bnip5 BH3. The intermolecular association appeared to be typical at first glance, but we found that it is maintained by tight hydrophobic interactions together with hydrogen/ionic bonds, which accounts for their high binding affinity with a dissociation constant of 775 nM. Structural analysis of the complex showed that Bnip5 interacts with Bak in a manner similar to that of the Bak‐activating pro‐apoptotic factor peroxisomal testis‐enriched protein 1, particularly in the destabilization of the intramolecular electrostatic network of Bak. Our structure is considered to reflect the initial point of drastic and consecutive conformational and stoichiometric changes in Bak induced by Bnip5 BH3, which helps in explaining the effects of Bnip5 in regulating Bak‐mediated apoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Disease Target Structure Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
- Critical Diseases Diagnostics Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
- Department of Biochemistry, Chungnam National University, Daejeon, Republic of Korea.
- Department of Biology, Chungnam National University, Daejeon, Republic of Korea.
- Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
ORCID-Profile: Bonsu Ku
Förderung
- Korea Research Institute of Bioscience and Biotechnology
- National Research Council of Science and Technology
- National Research Foundation of Korea
Zitieren
APA
Lim, D., Jeong, D. E., Shin, H. C., Choi, J. S., Seo, J., Kim, S. J., & Ku, B. (2024). Crystal structure of Bak bound to the BH3 domain of Bnip5, a noncanonical BH3 domain‐containing protein. Proteins: Structure, Function, and Bioinformatics. https://doi.org/10.1002/prot.26568
Vancouver
Lim D, Jeong DE, Shin HC, Choi JS, Seo J, Kim SJ, et al. Crystal structure of Bak bound to the BH3 domain of Bnip5, a noncanonical BH3 domain‐containing protein. Proteins: Structure, Function, and Bioinformatics. 2024. doi:10.1002/prot.26568
BibTeX
@article{Lim2024,
author = {Lim, Dahwan and Jeong, Da Eun and Shin, Ho-Chul and Choi, Joon Sig and Seo, Jinho and Kim, Seung Jun and Ku, Bonsu},
title = {Crystal structure of Bak bound to the BH3 domain of Bnip5, a noncanonical BH3 domain‐containing protein},
journal = {Proteins: Structure, Function, and Bioinformatics},
year = {2024},
doi = {10.1002/prot.26568}
}
EUVIMED